Literature DB >> 33833397

CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity.

Eun-Sook Kim1, Su-Min Nam1, Hye Kyung Song2, Seungeun Lee1, Kyoungmee Kim1, Hyun Kyung Lim1, Hyunsook Lee1, Kyu-Tae Kang1, Yeo-Jung Kwon3, Young-Jin Chun3, So Yeon Park4, Joohee Jung5, Aree Moon6.   

Abstract

Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a poor prognosis for which no effective therapeutic measures are currently available. The present study aimed to investigate whether interactions with endothelial colony-forming cells (ECFCs) promote aggressive progression of TNBC cells. Herein, using an indirect co-culture system, we showed that co-culture increased the invasive and migratory phenotypes of both MDA-MB-231 TNBC cells and ECFCs. Through a cytokine antibody array and RT-PCR analysis, we revealed that co-culture markedly induced secretion of the chemokine C-C motif ligand (CCL)8 from ECFCs and that of interleukin (IL)-8 from MDA-MB-231 cells. CCL8 was crucial for ECFC-induced IL-8 secretion and invasion of MDA-MB-231 cells as well as for MDA-MB-231-enhanced MMP-2 secretion and angiogenesis of ECFCs. We suggest c-Jun as a transcription factor for CCL8-induced IL-8 expression in MDA-MB-231 cells. IL-8 was important for co-culture-induced CCL8 and MMP-2 upregulation and invasion of ECFCs. Notably, our findings reveal a positive feedback loop between CCL8 and IL-8, which contributes to the aggressive phenotypes of both ECFC and TNBC cells. Using an MDA-MB-231 cell-based xenograft model, we show that tumor growth and metastasis are increased by co-injected ECFCs in vivo. Increased expression of IL-8 was observed in tissues with bone metastases in mice injected with conditioned media from co-cultured cells. High IL-8 levels are correlated with poor recurrence-free survival in TNBC patients. Together, these results suggest that CCL8 and IL-8 mediate the crosstalk between ECFCs and TNBC, leading to aggravation of tumorigenicity in TNBC.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33833397     DOI: 10.1038/s41388-021-01758-w

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

1.  In vivo vasculogenic potential of human blood-derived endothelial progenitor cells.

Authors:  Juan M Melero-Martin; Zia A Khan; Arnaud Picard; Xiao Wu; Sailaja Paruchuri; Joyce Bischoff
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

2.  Impact of the spheroid model complexity on drug response.

Authors:  Oliver Ingo Hoffmann; Christian Ilmberger; Stefanie Magosch; Mareile Joka; Karl-Walter Jauch; Barbara Mayer
Journal:  J Biotechnol       Date:  2015-03-03       Impact factor: 3.307

3.  LYG-202 inhibits activation of endothelial cells and angiogenesis through CXCL12/CXCR7 pathway in breast cancer.

Authors:  Kai Zhao; Yuyuan Yao; Xuwei Luo; Binyan Lin; Yujie Huang; Yuxin Zhou; Zhiyu Li; Qinglong Guo; Na Lu
Journal:  Carcinogenesis       Date:  2018-04-05       Impact factor: 4.944

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells.

Authors:  Nikolai N Khodarev; Jianqing Yu; Edwardine Labay; Thomas Darga; Charles K Brown; Helena J Mauceri; Reza Yassari; Nalin Gupta; Ralph R Weichselbaum
Journal:  J Cell Sci       Date:  2003-03-15       Impact factor: 5.285

6.  Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients.

Authors:  Wen-Jin Yin; Jin-Song Lu; Gen-Hong Di; Yan-Ping Lin; Li-Heng Zhou; Guang-Yu Liu; Jiong Wu; Kun-Wei Shen; Qi-Xia Han; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  Breast Cancer Res Treat       Date:  2008-06-18       Impact factor: 4.872

Review 7.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

8.  Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling.

Authors:  Wenwen Zhang; Jing Xu; Hehui Fang; Lin Tang; Weiwei Chen; Qian Sun; Qun Zhang; Fang Yang; Zijia Sun; Lulu Cao; Yucai Wang; Xiaoxiang Guan
Journal:  FASEB J       Date:  2017-09-12       Impact factor: 5.191

9.  CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro.

Authors:  D Delia; M G Lampugnani; M Resnati; E Dejana; A Aiello; E Fontanella; D Soligo; M A Pierotti; M F Greaves
Journal:  Blood       Date:  1993-02-15       Impact factor: 22.113

Review 10.  Role of endothelial progenitor cells in breast cancer angiogenesis: from fundamental research to clinical ramifications.

Authors:  Xuefen Le Bourhis; Rodrigue Romon; Hubert Hondermarck
Journal:  Breast Cancer Res Treat       Date:  2009-12-24       Impact factor: 4.872

View more
  4 in total

Review 1.  Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.

Authors:  Qiaorui Tan; Sha Yin; Dongdong Zhou; Yajing Chi; Xiaochu Man; Huihui Li
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

Review 2.  The pleiotropic roles of adipocyte secretome in remodeling breast cancer.

Authors:  Xiaomei Zhou; Jun Zhang; Wenchang Lv; Chongru Zhao; Yu Xia; Yiping Wu; Qi Zhang
Journal:  J Exp Clin Cancer Res       Date:  2022-06-14

Review 3.  Stromal Co-Cultivation for Modeling Breast Cancer Dormancy in the Bone Marrow.

Authors:  Robert Wieder
Journal:  Cancers (Basel)       Date:  2022-07-09       Impact factor: 6.575

4.  Association of serum Interleukin-8 level with lymph node metastasis and tumor recurrence in gastric cancer.

Authors:  Xiang Li; Guiping Xie; Jing Zhai; Yani He; Tongya Wang; Yaohui Wang; Lizong Shen
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.